These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19077379)

  • 1. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy.
    Oberg K; Ferone D; Kaltsas G; Knigge UP; Taal B; Plöckinger U; ;
    Neuroendocrinology; 2009; 90(2):209-13. PubMed ID: 19077379
    [No Abstract]   [Full Text] [Related]  

  • 2. [Biotherapy of neuroendocrine tumors].
    Chanson P; Ducreux M
    Rev Prat; 2002 Feb; 52(3):280-4. PubMed ID: 11925718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors.
    Eriksson B; Annibale B; Bajetta E; Mitry E; Pavel M; Platania M; Salazar R; Plöckinger U; ;
    Neuroendocrinology; 2009; 90(2):214-9. PubMed ID: 19713713
    [No Abstract]   [Full Text] [Related]  

  • 4. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs.
    Kwekkeboom DJ; Krenning EP; Lebtahi R; Komminoth P; Kos-Kudła B; de Herder WW; Plöckinger U; ;
    Neuroendocrinology; 2009; 90(2):220-6. PubMed ID: 19713714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine tumors. Biotherapy.
    Plöckinger U; Wiedenmann B
    Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):145-62. PubMed ID: 17382270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy and biotherapy in neuroendocrine tumors.
    Oberg K
    Curr Opin Oncol; 1993 Jan; 5(1):110-20. PubMed ID: 8094014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemoembolization, immunotherapy and hormone therapy of carcinoid and digestive neuroendocrine tumors].
    Gouyon B; Ruszniewski P
    Ann Gastroenterol Hepatol (Paris); 1995; 31(2):121-3. PubMed ID: 7618834
    [No Abstract]   [Full Text] [Related]  

  • 8. Somatostatin-receptor mediated diagnosis and treatment in gastrointestinal neuroendocrine tumours (GEP-NET's).
    Oberg K
    Rocz Akad Med Bialymst; 2005; 50():62-8. PubMed ID: 16358941
    [No Abstract]   [Full Text] [Related]  

  • 9. Emerging therapeutic options for advanced enteropancreatic neuroendocrine tumors.
    Dasanu CA; Majumder S; Gopal S; Stoica-Mustafa E; Trikudanathan G
    Expert Opin Pharmacother; 2012 Mar; 13(4):461-71. PubMed ID: 22292707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effect of somatostatin analogs in neuroendocrine tumors.
    Chua YJ; Michael M; Zalcberg JR; Hicks RJ; Goldstein D; Liauw W; Price T
    J Clin Oncol; 2010 Jan; 28(3):e41-2; author reply e43-4. PubMed ID: 20008618
    [No Abstract]   [Full Text] [Related]  

  • 11. Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.
    Janson ET; Oberg K
    Cancer Chemother Biol Response Modif; 2003; 21():535-46. PubMed ID: 15338762
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors.
    Pivonello R; Ferone D; Filippella M; Faggiano A; De Martino MC; Auriemma RS; Rota F; Lombardi G; Colao A
    J Endocrinol Invest; 2003; 26(8 Suppl):82-8. PubMed ID: 15233220
    [No Abstract]   [Full Text] [Related]  

  • 13. Current treatments of neuroendocrine tumors role of biotherapy and chemotherapy.
    Della Torre S; Procopio G; Fusi A; Catena L; Ferrari L; Nova P; Denaro A; Bichisao E; Bajetta E
    Tumori; 2003; 89(2):111-6. PubMed ID: 12841654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the treatment of neuroendocrine tumors.
    Bajetta E; Procopio G; Ferrari L; Catena L; Del Vecchio M; Bombardieri E
    Expert Rev Anticancer Ther; 2003 Oct; 3(5):631-42. PubMed ID: 14599087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?
    Fazio N; de Braud F; Delle Fave G; Öberg K
    Ann Oncol; 2007 Jan; 18(1):13-19. PubMed ID: 16798833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of prolonged-release somatostatin analog monotherapy in metastatic endocrine tumors].
    Kanyinda-K JM; Samalin E; Sebah H; Gallix B; Ychou M
    Gastroenterol Clin Biol; 2008 Dec; 32(12):989-91. PubMed ID: 18945567
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of somatostatin analogues in the treatment of neuroendocrine tumours.
    Grozinsky-Glasberg S; Grossman AB; Korbonits M
    Mol Cell Endocrinol; 2008 May; 286(1-2):238-50. PubMed ID: 18037561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnostic and therapeutic opportunities in neuroendocrine tumors of the gastroenteropancreatic system].
    Bolanowski M; Kos-Kudła B
    Postepy Hig Med Dosw (Online); 2005; 59():48-55. PubMed ID: 15761386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: pre- and perioperative therapy in patients with neuroendocrine tumors.
    Akerström G; Falconi M; Kianmanesh R; Ruszniewski P; Plöckinger U; ;
    Neuroendocrinology; 2009; 90(2):203-8. PubMed ID: 19713712
    [No Abstract]   [Full Text] [Related]  

  • 20. Neuroendocrine cancer: CLARINET: new option for NETs.
    Hutchinson L
    Nat Rev Clin Oncol; 2014 Sep; 11(9):501. PubMed ID: 25073004
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.